Trial Profile
Efficacy of 12 weeks treatment with Sofosbuvir/Velpatasvir in HCV Genotype 3 Patients with Compensated Cirrhosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Aug 2022
Price :
$35
*
At a glance
- Drugs Sofosbuvir/velpatasvir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 26 Jun 2022 Results presented at The International Liver Congress 2022
- 10 Dec 2018 New trial record